Liquida Misses Full Approval for Pulmonary Hypertension Drug as Competitor Retains Market Exclusivity

The FDA on Monday only granted Liquida’s Yutrepia tentative approval, keeping it off the U.S. market until after rival United Therapeutics’ exclusivity expires in May 2025.